Upstate Active Clinical Trials
Study Title:2215-CL-0302: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of FLT3 Inhibitor Gileritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission
Upstate Institutional Review Board (IRB) Number:976763
Study Phase:Phase 3
Patient Age Group:Adults
Principal Investigator:Teresa C Gentile, MD, PhD
What is involved if I participate?
- Is transportation provided or reimbursed?
- Is parking provided or reimbursed?
Where will the study take place?Upstate Cancer Center - All Procedures
Who can I contact for more information?
Name: Erinn Mcdowell, MS, CCRP